Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Kidney Int. 2019 Feb 21;95(6):1347–1358. doi: 10.1016/j.kint.2018.11.027

Figure 6. KO RBP-Jκ in bone marrow-derived FSP-1+ cells increases AVF patency.

Figure 6.

A. Generation of RBP-jκflox/flox/FSP-1-Cre+ mice. B. KO of RBP-Jκ in bone marrow FSP-1+ cells was verified by Western blot. C. Decreases in cytokine production in AVFs (4 weeks) from specific RBP-Jκ deficiency mice were detected by real-time RT-PCR. D & E. At 4 weeks after creating the AVF in CKD mice, specific KO of RBP-Jκ in FSP-1 cells in AVFs were determined by double immunostaining of FSP-1 and RBP-Jκ. White arrows point to RBP-Jκ/FSP-1+ inflammatory cells. F & G. Representative image and densitometry analysis of SMMHC in AVFs created in WTRBP-Jκ BM-KO mice or control WTWT BM mice. H. Summary of morphometrical analysis shown as area ratio of lumen and neointima (n = 6, *, p < 0.05 vs WT). Scale bar = 50 μm in all panels.

HHS Vulnerability Disclosure